| Revenue growth | 56.21% YoY growth in FY26. |
|---|---|
| Margins | EBITDA margin at 16.7% in FY26 vs 20.7% in FY25. |
| Order book | Healthy order book mentioned by MD. |
| Demand visibility | Robust momentum in core export markets: Africa, SE Asia, Latin America. |
| Management confidence | High; confident in profitability improvement as investments yield results. |
Growth
Revenue grew 56.21% YoY to ₹89.6 cr; PAT increased 42.3% YoY to ₹9.67 cr.
Outlook
Focus on 100+ products under registration and scaling CDMO capacity to improve operating leverage.
Risks
Margins impacted by product mix changes, upfront registration costs, and compliance-related expenses.
Earnings Call filed with NSE, NSE: ACCPL. Summary written with AI assistance from the document.
Accretion Pharmaceuticals Ltd: key numbers
- Share price
- ₹185.30
- Market cap
- ₹206.0 Cr
- Revenue (annual)
- ₹89.63 Cr
- Net profit (annual)
- ₹9.67 Cr
- P/E (TTM)
- 21.3×Sector 47.4×
- Promoter holding
- 73.52%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Accretion Pharmaceuticals Ltd
All →Accretion Pharmaceuticals Annual General Meeting
Accretion Pharmaceuticals Limited issued a postal ballot notice to shareholders to seek approval for altering the company's Memorandum of Association (Object Clause).
Accretion Pharmaceuticals Other Announcement
Accretion Pharmaceuticals Limited approved an alteration to its Memorandum of Association to expand its business objects. The Board also approved increased borrowing and investment limits subject to shareholder approval.
Accretion Pharmaceuticals Annual General Meeting
Accretion Pharmaceuticals Limited held its 3rd Annual General Meeting on August 27, 2026. The meeting transacted business including the adoption of financial statements and director re-appointment.
Accretion Pharmaceuticals Other Announcement
Accretion Pharmaceuticals Limited has provided the web link for shareholders to access its Annual Report for FY 2025-26 and the 3rd AGM notice.
Accretion Pharmaceuticals Annual General Meeting
Accretion Pharmaceuticals Limited has scheduled its 3rd Annual General Meeting for August 27, 2026, to be conducted through video conferencing for ordinary business transactions.
Accretion Pharmaceuticals Management Change
Accretion Pharmaceuticals' HR Manager, Ms. Bandana Kumari, resigned effective 2nd July 2026. The resignation is for personal reasons, with no material issues reported.